Cwm LLC Raises Stake in Biohaven Ltd. $BHVN

Cwm LLC increased its stake in Biohaven Ltd. (NYSE:BHVN) by 488.9% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 65,719 shares of the company’s stock after buying an additional 54,560 shares during the quarter. Cwm LLC’s holdings in Biohaven were worth $742,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. PNC Financial Services Group Inc. boosted its holdings in shares of Biohaven by 113.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock worth $36,000 after buying an additional 1,268 shares during the last quarter. Focus Partners Wealth purchased a new position in shares of Biohaven in the 3rd quarter worth about $87,000. Tower Research Capital LLC TRC boosted its holdings in shares of Biohaven by 198.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,031 shares of the company’s stock worth $113,000 after buying an additional 5,341 shares during the last quarter. Quantbot Technologies LP boosted its holdings in shares of Biohaven by 1,097.8% in the 2nd quarter. Quantbot Technologies LP now owns 8,840 shares of the company’s stock worth $125,000 after buying an additional 8,102 shares during the last quarter. Finally, Osaic Holdings Inc. boosted its holdings in shares of Biohaven by 150.5% in the 2nd quarter. Osaic Holdings Inc. now owns 9,791 shares of the company’s stock worth $147,000 after buying an additional 5,883 shares during the last quarter. 88.78% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently weighed in on BHVN. HC Wainwright cut their price target on shares of Biohaven from $11.00 to $10.00 and set a “neutral” rating on the stock in a report on Wednesday, March 4th. Morgan Stanley cut their price target on shares of Biohaven from $26.00 to $21.00 and set an “overweight” rating on the stock in a report on Tuesday, January 6th. Citigroup increased their price target on Biohaven from $14.00 to $17.00 and gave the stock a “buy” rating in a research note on Thursday, April 2nd. The Goldman Sachs Group upgraded Biohaven to a “strong-buy” rating in a research note on Friday, February 6th. Finally, Wall Street Zen downgraded Biohaven from a “sell” rating to a “strong sell” rating in a research note on Sunday. Three equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $22.53.

Biohaven Price Performance

Shares of NYSE:BHVN opened at $9.20 on Thursday. The company has a quick ratio of 3.18, a current ratio of 3.18 and a debt-to-equity ratio of 4.59. The firm has a market capitalization of $1.38 billion, a PE ratio of -1.32 and a beta of 1.34. Biohaven Ltd. has a twelve month low of $7.48 and a twelve month high of $24.06. The company has a 50-day moving average price of $9.95 and a two-hundred day moving average price of $11.15.

Biohaven (NYSE:BHVN) last issued its earnings results on Monday, March 2nd. The company reported ($1.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.01. Equities analysts forecast that Biohaven Ltd. will post -2.98 EPS for the current year.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.